Local delivery of basic fibroblast growth factor increases both angiogenesis and engraftment of hepatocytes in tissue-engineered polymer devices

被引:91
作者
Lee, H
Cusick, RA
Browne, F
Kim, TH
Ma, PX
Utsunomiya, H
Langer, R
Vacanti, JP
机构
[1] Univ Calif San Francisco, Fetal Treatment Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[3] Childrens Hosp, Dept Surg Res, Boston, MA USA
[4] MIT, Dept Chem Engn, Cambridge, MA USA
[5] Massachusetts Gen Hosp, Dept Surg, Boston, MA USA
关键词
D O I
10.1097/00007890-200205270-00011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. We investigated heterotopic hepatocyte transplantation on biodegradable polymers as a potential treatment for end-stage liver disease. The primary problem has been insufficient engraftment of transplanted cells partly because of insufficient vascularization. Increasing vascularization through locally delivered angiogenic factors may increase angiogenesis and hepatocyte engraftment. Methods. We studied the effect of local delivery of basic fibroblast growth factor (bFGF) on angiogenesis and hepatocyte engraftment within tissue-engineered liver constructs. Poly-L-lactic acid discs were fabricated and coated with either a mixture of saline, sucralfate, and Hydron (control group) or bFGF, sucralfate, and Hydron (bFGF group). bFGF release from polymers in vitro was tested using an ELISA. Hepatocytes were isolated from Lewis rats, seeded on control (n=9) or bFGF (n=11) polymers, and implanted into the small bowel mesentery of syngeneic animals. Specimens were harvested after 2 weeks and analyzed for hepatocyte engraftment. Microvascular density was compared between control (n=6) and bFGF groups (n=5). Results. Three hundred twenty-three thousandths of a microgram of bFGF were incorporated per polymer. Greater than 99% of the bFGF was released into solution by 72 hr in vitro. Two weeks after implantation, microvascular density, as measured by capillaries per high-powered field (c/hpf), was significantly greater in the bFGF group (43.8 c/hpf), compared with the control group (30.5 c/hpf, P<0.005). Specimens from the bFGF group (mean engraftment, 61,355 mum(2)) showed a 2.5-fold increase in hepatocyte engraftment as compared with control (24,197 mum(2); P<0.002). Conclusions. The angiogenic growth factor bFGF can be incorporated into degradable polymers used as delivery devices for hepatocyte transplantation. Implantation of these devices increases angiogenesis into the device and increases hepatocyte engraftment.
引用
收藏
页码:1589 / 1593
页数:5
相关论文
共 17 条
[1]   STUDIES IN RAT-LIVER PERFUSION FOR OPTIMAL HARVEST OF HEPATOCYTES [J].
AIKEN, J ;
CIMA, L ;
SCHLOO, B ;
MOONEY, D ;
JOHNSON, L ;
LANGER, R ;
VACANTI, JP .
JOURNAL OF PEDIATRIC SURGERY, 1990, 25 (01) :140-145
[2]  
Cusick Robert A., 1995, Surgical Forum, V46, P658
[3]   THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[4]  
*DIV TRANSPL OFF S, 1995, ANN REP US SCI REG T
[5]  
KAUFMANN PM, 1994, TRANSPL P, V26, P3343
[6]   TISSUE ENGINEERING [J].
LANGER, R ;
VACANTI, JP .
SCIENCE, 1993, 260 (5110) :920-926
[7]   Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor [J].
Loughnan, MS ;
Chatzistefanou, K ;
Gonzalez, EM ;
Flynn, E ;
Adamis, AP ;
Shing, Y ;
DAmato, RJ ;
Folkman, J .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, 1996, 24 (03) :289-295
[8]   LAMINATED 3-DIMENSIONAL BIODEGRADABLE FOAMS FOR USE IN TISSUE ENGINEERING [J].
MIKOS, AG ;
SARAKINOS, G ;
LEITE, SM ;
VACANTI, JP ;
LANGER, R .
BIOMATERIALS, 1993, 14 (05) :323-330
[9]  
MOONEY DJ, 1994, TRANSPLANT P, V26, P3425
[10]  
*NAT CTR HLTH STAT, 2000, NATL VITAL STAT REPO, V49, P5